Regulus Therapeutics Inc. (RGLS): Price and Financial Metrics
GET POWR RATINGS... FREE!
RGLS Stock Price Chart Interactive Chart >
RGLS Price/Volume Stats
| Current price | $1.44 | 52-week high | $3.70 |
| Prev. close | $1.41 | 52-week low | $1.08 |
| Day low | $1.40 | Volume | 50,804 |
| Day high | $1.50 | Avg. volume | 44,715 |
| 50-day MA | $1.48 | Dividend yield | N/A |
| 200-day MA | $1.84 | Market Cap | 21.07M |
Regulus Therapeutics Inc. (RGLS) Company Bio
Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. The company was founded in 2007 and is based in San Diego, California.
Latest RGLS News From Around the Web
Below are the latest news stories about REGULUS THERAPEUTICS INC that investors may wish to consider to help them evaluate RGLS as an investment opportunity.
Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the grant of an inducement stock option to Claire Padgett, Ph.D. and to Rekha Garg, M.D., M.S., on January 11, 2023 in connection with their respective appointments as Regulus' Senior Vice President, Clinical Operations and Senior Vice President, Clinical Development and Regulatory. The grants in a |
Sanofi Opts To Terminate Rare Disease Program With Regulus TherapeuticsSanofi SA (NASDAQ: SNY) elected to terminate its second amended and restated collaboration and license agreement with Regulus Therapeutics Inc (NASDAQ: RGLS), initially announced in 2014. In July 2022, Sanofi decided to terminate the Phase 2 clinical study of lademirsen for Alport syndrome for failure to meet Sanofi’s pre-defined futility criteria. Safety issues forced a revamp of that late-stage program when Sanofi flagged a failure for its microRNA drug lademirsen. At that time, Sanofi was eva |
Regulus Therapeutics Announces Resignation of Board MemberRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Simos Simeonidis, Ph.D., member of the Board of Directors, has stepped down from the Board, due to the time requirements of his recent appointment as co-Chief Executive Officer and co-Chief Investment Officer at Ally Bridge Group. His resignation was effective December 6, 2022. |
13 Best Biotech Penny Stocks To Buy NowIn this article, we will be taking a look at the 13 best biotech penny stocks to buy now. To skip our detailed analysis of these stocks, you can go directly to see the 5 Best Biotech Penny Stocks To Buy Now. Biotechnology is a sector that has long been contributing to the improvement of […] |
Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical OperationsRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointments of Rekha Garg, M.D., M.S., to Senior Vice President, Clinical Development and Regulatory, and Claire Padgett, Ph.D. to Senior Vice President, Clinical Operations. The company also announced the promotion of Morgan Carlson, Ph.D., to Vice President, Biology and Edmund Lee, Ph.D., to |
RGLS Price Returns
| 1-mo | 5.11% |
| 3-mo | -0.69% |
| 6-mo | -15.29% |
| 1-year | -41.63% |
| 3-year | -86.67% |
| 5-year | -99.00% |
| YTD | 5.11% |
| 2022 | -56.51% |
| 2021 | -76.67% |
| 2020 | 51.69% |
| 2019 | -4.30% |
| 2018 | -92.55% |
Continue Researching RGLS
Here are a few links from around the web to help you further your research on Regulus Therapeutics Inc's stock as an investment opportunity:Regulus Therapeutics Inc (RGLS) Stock Price | Nasdaq
Regulus Therapeutics Inc (RGLS) Stock Quote, History and News - Yahoo Finance
Regulus Therapeutics Inc (RGLS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...